ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 477,07
0,21%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Prothena Corporation PLC (PRTA)

  7. Prothena Corporation PLC (PRTA) Actualités

PRTA

Prothena (PRTA)

Prothena Corporation PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PRTA
DateHeureSourceTitreSymboleSociété
28/05/202422h05Business WireProthena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development CollaborationNASDAQ:PRTAProthena Corporation PLC
17/05/202422h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRTAProthena Corporation PLC
17/05/202422h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRTAProthena Corporation PLC
08/05/202422h19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRTAProthena Corporation PLC
08/05/202422h05Business WireProthena Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
01/05/202422h05Business WireProthena to Report First Quarter 2024 Financial Results on May 8NASDAQ:PRTAProthena Corporation PLC
15/04/202422h05Business WireProthena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & LymphomaNASDAQ:PRTAProthena Corporation PLC
06/03/202403h01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PRTAProthena Corporation PLC
05/03/202422h05Business WireProthena to Participate in Upcoming Healthcare ConferencesNASDAQ:PRTAProthena Corporation PLC
04/03/202422h05Business WireProthena Appoints David Ford to Newly Created Chief People Officer PositionNASDAQ:PRTAProthena Corporation PLC
22/02/202423h29Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PRTAProthena Corporation PLC
22/02/202422h56Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRTAProthena Corporation PLC
21/02/202422h05Business WireProthena Announces Appointment of Daniel G. Welch as Director and Chair DesignateNASDAQ:PRTAProthena Corporation PLC
15/02/202422h05Business WireProthena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
14/02/202418h16Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PRTAProthena Corporation PLC
14/02/202401h49Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PRTAProthena Corporation PLC
08/02/202422h05Business WireProthena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024NASDAQ:PRTAProthena Corporation PLC
24/01/202422h06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PRTAProthena Corporation PLC
08/01/202414h30Business WireProthena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio ProgramsNASDAQ:PRTAProthena Corporation PLC
02/11/202321h05Business WireProthena Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
26/10/202322h05Business WireProthena to Report Third Quarter 2023 Financial Results on November 2NASDAQ:PRTAProthena Corporation PLC
03/08/202323h14Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PRTAProthena Corporation PLC
03/08/202322h05Business WireProthena Reports Second Quarter 2023 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
27/07/202322h05Business WireProthena to Report Second Quarter 2023 Financial Results on August 3NASDAQ:PRTAProthena Corporation PLC
17/07/202314h35Business WireProthena Presents New Research in the Treatment of Alzheimer’s Disease at Alzheimer’s Association International Conference® 2023 (AAIC®)NASDAQ:PRTAProthena Corporation PLC
11/07/202322h05Business WireProthena to Present New Data from Alzheimer’s Disease Programs at Alzheimer’s Association International Conference® 2023 (AAIC®)NASDAQ:PRTAProthena Corporation PLC
10/07/202322h10Business WireProthena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau AntibodyNASDAQ:PRTAProthena Corporation PLC
27/06/202322h05Business WireProthena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with BirtamimabNASDAQ:PRTAProthena Corporation PLC
21/06/202312h00Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PRTAProthena Corporation PLC
20/06/202322h39Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:PRTAProthena Corporation PLC
 Showing the most relevant articles for your search:NASDAQ:PRTA

Dernières Valeurs Consultées

NASDAQ
GOOGL
Alphabet
EU
RNO
Renault
EU
CAP
Capgemini
EU
PX1
CAC 40
FTSE
UKX
FTSE 100
NASDAQ
NVDA
NVIDIA
EU
EN
Bouygues
NASDAQ
MSFT
Microsoft
EU
ACA
Credit Agricole
COIN
ETHUSD
Ethereum
EU
BN
Danone
EU
GLE
Societe Generale
EU
AF
Air FranceKLM
NYSE
KO
Coca Cola
EU
ORA
Orange
NYSE
JPM
JP Morgan Chase
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés